Cardiff Lexington（CDIX）株式概要カーディフ・レキシントン・コーポレーションは、その子会社とともに米国のヘルスケア業界で事業を展開している。 詳細CDIX ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きいキャッシュランウェイが1年未満である 過去5年間で収益は年間33.2%減少しました。 過去1年間で株主の希薄化は大幅に進んだ +1 さらなるリスクすべてのリスクチェックを見るCDIX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW482,187 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA482,187 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.2652.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m13m2016201920222025202620282031Revenue US$11.5mEarnings US$857.2kAdvancedSet Fair ValueView all narrativesCardiff Lexington Corporation 競合他社Basel Medical GroupSymbol: NasdaqCM:BMGLMarket cap: US$8.2mVivos TherapeuticsSymbol: NasdaqCM:VVOSMarket cap: US$4.2mNewGenIvf GroupSymbol: NasdaqCM:NIVFMarket cap: US$3.6mAmerican Shared Hospital ServicesSymbol: NYSEAM:AMSMarket cap: US$10.3m価格と性能株価の高値、安値、推移の概要Cardiff Lexington過去の株価現在の株価US$0.2652週高値US$12.0052週安値US$0.25ベータ1.971ヶ月の変化-71.11%3ヶ月変化-86.17%1年変化-94.22%3年間の変化-98.85%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Aug 06Cardiff Lexington Corporation to Report Q2, 2026 Results on Aug 12, 2026Cardiff Lexington Corporation announced that they will report Q2, 2026 results on Aug 12, 2026お知らせ • May 14Cardiff Lexington Corporation to Report Q1, 2026 Results on May 19, 2026Cardiff Lexington Corporation announced that they will report Q1, 2026 results on May 19, 2026お知らせ • May 01Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,739,130 Price\Range: $3.45 Discount Per Security: $0.276 Transaction Features: Sponsor Backed Offeringお知らせ • Mar 12Cardiff Lexington Corporation to Report Q4, 2025 Results on Mar 16, 2026Cardiff Lexington Corporation announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Mar 16, 2026お知らせ • Jan 06Cardiff Lexington Corporation Announces Board Changes, Effective December 31, 2025On December 31, 2025, Daniel Thompson resigned from the Board of Directors of Cardiff Lexington Corporation (the “ Company”), including from his position as Chairman of the Board. Such resignation was not due to any disagreement with the Company on any matter relating to its operations, policies (including accounting or financial policies) or practices. Alex Cunningham, the Company’s Chief Executive Officer and member of the Board of Directors, was appointed as the new Chairman of the Board.お知らせ • Dec 16Cardiff Lexington Corporation has filed an IPO in the amount of $6 million.Cardiff Lexington Corporation has filed an IPO in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock最新情報をもっと見るRecent updatesお知らせ • Aug 06Cardiff Lexington Corporation to Report Q2, 2026 Results on Aug 12, 2026Cardiff Lexington Corporation announced that they will report Q2, 2026 results on Aug 12, 2026お知らせ • May 14Cardiff Lexington Corporation to Report Q1, 2026 Results on May 19, 2026Cardiff Lexington Corporation announced that they will report Q1, 2026 results on May 19, 2026お知らせ • May 01Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,739,130 Price\Range: $3.45 Discount Per Security: $0.276 Transaction Features: Sponsor Backed Offeringお知らせ • Mar 12Cardiff Lexington Corporation to Report Q4, 2025 Results on Mar 16, 2026Cardiff Lexington Corporation announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Mar 16, 2026お知らせ • Jan 06Cardiff Lexington Corporation Announces Board Changes, Effective December 31, 2025On December 31, 2025, Daniel Thompson resigned from the Board of Directors of Cardiff Lexington Corporation (the “ Company”), including from his position as Chairman of the Board. Such resignation was not due to any disagreement with the Company on any matter relating to its operations, policies (including accounting or financial policies) or practices. Alex Cunningham, the Company’s Chief Executive Officer and member of the Board of Directors, was appointed as the new Chairman of the Board.お知らせ • Dec 16Cardiff Lexington Corporation has filed an IPO in the amount of $6 million.Cardiff Lexington Corporation has filed an IPO in the amount of $6 million. Security Name: Common Stock Security Type: Common Stockお知らせ • Nov 07Cardiff Lexington Corporation to Report Q3, 2025 Results on Nov 14, 2025Cardiff Lexington Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 14, 2025お知らせ • Aug 15Cardiff Lexington Corporation announced delayed 10-Q filingOn 08/14/2025, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 29Cardiff Lexington Corporation to Report Q2, 2025 Results on Aug 12, 2025Cardiff Lexington Corporation announced that they will report Q2, 2025 results on Aug 12, 2025お知らせ • May 03Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 to $6 Discount Per Security: $0.45お知らせ • Jun 13Cardiff Lexington Corporation Announces Executive ChangesOn June 5, 2024, Cardiff Lexington Corporation announced termination Zia Choe from her position as Chief Accounting Officer of the Company in connection with a restructuring of the Company’s accounting department. The Company’s Chief Financial Officer, Matthew T. Shafer, will serve as the Company’s principal accounting officer and the Company has hired a new Controller and Staff Accountant to support Mr. Shafer.お知らせ • Jan 17Cardiff Lexington Appoints Kevin Fitzgerald as Managing Director of Nova Ortho and SpineCardiff Lexington Corporation announced the appointment of Dr. Kevin Fitzgerald, M.D. as Managing Director of Nova Ortho and Spine, the Company's healthcare subsidiary. Dr. Fitzgerald has previously been with Nova Ortho and Spine as a highly qualified member of the management and care team. In his new role as managing director, he will now oversee all aspects of day to day operations, expansion, patient care, provider production, marketing, and company relations as the business continues to grow. Dr. Fitzgerald has over 20 years of experience in the medical profession in various roles including physician, respiratory therapist, and physician's assistant. From 2018 to 2021, Dr. Fitzgerald was the alternate Chief Medical Officer and the in-patient medical director for the Cleveland Clinic throughout Martin County, Florida. He also served as the Chairman of Medicine, Professional Development Physician Champion, Operations Development, Financial Committee Member, Board of Trustees (voting member), and an Instructor for Career Development and Patient Advocacy. In these roles, Dr. Fitzgerald was solely responsible for three hospitals with a total patient capacity of over 550, as well as the supervision of 30 physicians and 12 advanced care providers. Additionally, during his tenure, Dr. Fitzgerald developed several programs to include a physician advisory platform that allowed the hospital system to work closely with private and government insurance. This created a symbiotic relationship while improving care and increasing revenue. Dr. Fitzgerald also continues to serve as a Colonel and the Chief of Aerospace Medicine in the Air National Guard overseeing the state of Florida's entire health program of Aerospace and General Medicine. Dr. Fitzgerald is board certified by the American Academy for Procedural Medicine (AAOPM) for procedural medicine, certified traumatic brain injury specialist, and a life care planner for catastrophic injuries. He earned his Doctor of Medicine from the International University of Health and Sciences and completed his residency at Oakland University in Detroit, MI, a part of the Beaumont Health network, now one of the largest healthcare systems in Michigan. In addition to his medical degree, Dr. Fitzgerald has also earned a Bachelor of Science in physician assistant studies and a Master of Health Science from Nova Southeastern University, as well as a Bachelor of Science in Mass Communications from Towson University.お知らせ • Jan 05Cardiff Lexington Corporation Appoints Zia Choe as Chief Accounting OfficerCardiff Lexington Corporation announced the appointment of Zia Choe as Chief Accounting Officer. Ms. Choe previously served as interim Chief Financial Officer at Cardiff Lexington. In her new role, Ms. Choe will work across all constituencies to help ensure accurate and timely financial reporting, develop policies and procedures which align to enterprise-wide business strategies and accounting professional standards, perform technical accounting diligence on prospective acquisitions, and support on the execution of the Company's strategic growth initiatives to expand on a national scale. Ms. Choe is a highly accomplished finance professional with 17 years of accounting and operational experience. Most recently, Ms. Choe served as a Partner at STK Financial where she was responsible for the financial audit and review of domestic and international clients, provided high level outsourced accounting advisory services, performed financial due diligence for mergers and acquisitions, and assisted in the preparation of 10K and 10Q financial statements and footnotes. Prior to this role, Ms. Choe served as Audit and Assurance Manager at JNK Accountancy Group, where she successfully conducted financial audits in accordance with US GAAP and IFRS measures for various domestic and international clients. She also advised clients on various topics including accounting policies, internal control, risk assessments, fraud, and new accounting standards. Ms. Choe is a certified public accountant. She received her Bachelor of Science degree in hospitality management from Florida International University and her Master of Science equivalent in accounting from the AICPA Accounting Program at Ajou University in Suwon, South Korea.お知らせ • May 25Cardiff Lexington Corp. announced delayed 10-Q filingOn 05/24/2023, Cardiff Lexington Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 25Cardiff Lexington Corporation announced delayed amended 10-Q filingOn 08/24/2021, Cardiff Lexington Corporation announced that they will be unable to file their amended 10-Q by the deadline required by the SEC.お知らせ • Aug 17Cardiff Lexington Corporation announced delayed 10-Q filingOn 08/16/2021, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 05Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million.Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million on June 4, 2021. Under the terms, Cardiff paid $2.5 million in cash, 0.9 million J Preferred Stock and a performance based contingent supplement payment of 0.8 million shares. Leonite Capital and an affiliated institutional investor provided a capital investment into Cardiff Lexington Series N Preferred Stock of $3.5 million which facilitated Cardiff Lexington's cash payment portion of the acquisition to the Sellers. No operational changes are planned, and current ownership will remain in place under a ten (10) year Management Agreement. The subsidiary will serve as an acquisition platform to integrate complementary healthcare service providers in neighboring markets and ancillary service providers (chiropractic, physical therapy, imaging, etc.) as we meet rapidly expanding opportunities. Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million.株主還元CDIXUS HealthcareUS 市場7D-56.7%-0.4%-0.3%1Y-94.2%24.7%19.9%株主還元を見る業界別リターン: CDIX過去 1 年間で24.7 % の収益を上げたUS Healthcare業界を下回りました。リターン対市場: CDIXは、過去 1 年間で19.9 % のリターンを上げたUS市場を下回りました。価格変動Is CDIX's price volatile compared to industry and market?CDIX volatilityCDIX Average Weekly Movement32.1%Healthcare Industry Average Movement7.3%Market Average Movement7.1%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.1%安定した株価: CDIXの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CDIXの 週次ボラティリティ は過去 1 年間で49%から32%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a17Alex Cunninghamcardifflexington.comカーディフ・レキシントン・コーポレーションは、その子会社とともに米国のヘルスケア業界で事業を展開している。同社はヘルスケアと不動産の2つのセグメントで事業を展開している。同社は、骨格系および関連する骨、関節、腱、筋肉、靭帯、神経の損傷や障害に対する様々な診断および外科サービスを提供している。また、不動産事業も行っている。同社は以前はカーディフ・インターナショナル社として知られていたが、2018年1月にカーディフ・レキシントン・コーポレーションに社名変更した。カーディフ・レキシントン・コーポレーションはネバダ州ラスベガスを拠点としている。もっと見るCardiff Lexington Corporation 基礎のまとめCardiff Lexington の収益と売上を時価総額と比較するとどうか。CDIX 基礎統計学時価総額US$6.05m収益（TTM）-US$10.73m売上高(TTM)US$10.21m0.4xP/Sレシオ-0.4xPER（株価収益率CDIX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CDIX 損益計算書（TTM）収益US$10.21m売上原価US$4.04m売上総利益US$6.17mその他の費用US$16.90m収益-US$10.73m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）-0.70グロス・マージン60.42%純利益率-105.06%有利子負債／自己資本比率642.7%CDIX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/18 06:31終値2026/08/18 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cardiff Lexington Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 06Cardiff Lexington Corporation to Report Q2, 2026 Results on Aug 12, 2026Cardiff Lexington Corporation announced that they will report Q2, 2026 results on Aug 12, 2026
お知らせ • May 14Cardiff Lexington Corporation to Report Q1, 2026 Results on May 19, 2026Cardiff Lexington Corporation announced that they will report Q1, 2026 results on May 19, 2026
お知らせ • May 01Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,739,130 Price\Range: $3.45 Discount Per Security: $0.276 Transaction Features: Sponsor Backed Offering
お知らせ • Mar 12Cardiff Lexington Corporation to Report Q4, 2025 Results on Mar 16, 2026Cardiff Lexington Corporation announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Mar 16, 2026
お知らせ • Jan 06Cardiff Lexington Corporation Announces Board Changes, Effective December 31, 2025On December 31, 2025, Daniel Thompson resigned from the Board of Directors of Cardiff Lexington Corporation (the “ Company”), including from his position as Chairman of the Board. Such resignation was not due to any disagreement with the Company on any matter relating to its operations, policies (including accounting or financial policies) or practices. Alex Cunningham, the Company’s Chief Executive Officer and member of the Board of Directors, was appointed as the new Chairman of the Board.
お知らせ • Dec 16Cardiff Lexington Corporation has filed an IPO in the amount of $6 million.Cardiff Lexington Corporation has filed an IPO in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock
お知らせ • Aug 06Cardiff Lexington Corporation to Report Q2, 2026 Results on Aug 12, 2026Cardiff Lexington Corporation announced that they will report Q2, 2026 results on Aug 12, 2026
お知らせ • May 14Cardiff Lexington Corporation to Report Q1, 2026 Results on May 19, 2026Cardiff Lexington Corporation announced that they will report Q1, 2026 results on May 19, 2026
お知らせ • May 01Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,739,130 Price\Range: $3.45 Discount Per Security: $0.276 Transaction Features: Sponsor Backed Offering
お知らせ • Mar 12Cardiff Lexington Corporation to Report Q4, 2025 Results on Mar 16, 2026Cardiff Lexington Corporation announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Mar 16, 2026
お知らせ • Jan 06Cardiff Lexington Corporation Announces Board Changes, Effective December 31, 2025On December 31, 2025, Daniel Thompson resigned from the Board of Directors of Cardiff Lexington Corporation (the “ Company”), including from his position as Chairman of the Board. Such resignation was not due to any disagreement with the Company on any matter relating to its operations, policies (including accounting or financial policies) or practices. Alex Cunningham, the Company’s Chief Executive Officer and member of the Board of Directors, was appointed as the new Chairman of the Board.
お知らせ • Dec 16Cardiff Lexington Corporation has filed an IPO in the amount of $6 million.Cardiff Lexington Corporation has filed an IPO in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock
お知らせ • Nov 07Cardiff Lexington Corporation to Report Q3, 2025 Results on Nov 14, 2025Cardiff Lexington Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 14, 2025
お知らせ • Aug 15Cardiff Lexington Corporation announced delayed 10-Q filingOn 08/14/2025, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 29Cardiff Lexington Corporation to Report Q2, 2025 Results on Aug 12, 2025Cardiff Lexington Corporation announced that they will report Q2, 2025 results on Aug 12, 2025
お知らせ • May 03Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 to $6 Discount Per Security: $0.45
お知らせ • Jun 13Cardiff Lexington Corporation Announces Executive ChangesOn June 5, 2024, Cardiff Lexington Corporation announced termination Zia Choe from her position as Chief Accounting Officer of the Company in connection with a restructuring of the Company’s accounting department. The Company’s Chief Financial Officer, Matthew T. Shafer, will serve as the Company’s principal accounting officer and the Company has hired a new Controller and Staff Accountant to support Mr. Shafer.
お知らせ • Jan 17Cardiff Lexington Appoints Kevin Fitzgerald as Managing Director of Nova Ortho and SpineCardiff Lexington Corporation announced the appointment of Dr. Kevin Fitzgerald, M.D. as Managing Director of Nova Ortho and Spine, the Company's healthcare subsidiary. Dr. Fitzgerald has previously been with Nova Ortho and Spine as a highly qualified member of the management and care team. In his new role as managing director, he will now oversee all aspects of day to day operations, expansion, patient care, provider production, marketing, and company relations as the business continues to grow. Dr. Fitzgerald has over 20 years of experience in the medical profession in various roles including physician, respiratory therapist, and physician's assistant. From 2018 to 2021, Dr. Fitzgerald was the alternate Chief Medical Officer and the in-patient medical director for the Cleveland Clinic throughout Martin County, Florida. He also served as the Chairman of Medicine, Professional Development Physician Champion, Operations Development, Financial Committee Member, Board of Trustees (voting member), and an Instructor for Career Development and Patient Advocacy. In these roles, Dr. Fitzgerald was solely responsible for three hospitals with a total patient capacity of over 550, as well as the supervision of 30 physicians and 12 advanced care providers. Additionally, during his tenure, Dr. Fitzgerald developed several programs to include a physician advisory platform that allowed the hospital system to work closely with private and government insurance. This created a symbiotic relationship while improving care and increasing revenue. Dr. Fitzgerald also continues to serve as a Colonel and the Chief of Aerospace Medicine in the Air National Guard overseeing the state of Florida's entire health program of Aerospace and General Medicine. Dr. Fitzgerald is board certified by the American Academy for Procedural Medicine (AAOPM) for procedural medicine, certified traumatic brain injury specialist, and a life care planner for catastrophic injuries. He earned his Doctor of Medicine from the International University of Health and Sciences and completed his residency at Oakland University in Detroit, MI, a part of the Beaumont Health network, now one of the largest healthcare systems in Michigan. In addition to his medical degree, Dr. Fitzgerald has also earned a Bachelor of Science in physician assistant studies and a Master of Health Science from Nova Southeastern University, as well as a Bachelor of Science in Mass Communications from Towson University.
お知らせ • Jan 05Cardiff Lexington Corporation Appoints Zia Choe as Chief Accounting OfficerCardiff Lexington Corporation announced the appointment of Zia Choe as Chief Accounting Officer. Ms. Choe previously served as interim Chief Financial Officer at Cardiff Lexington. In her new role, Ms. Choe will work across all constituencies to help ensure accurate and timely financial reporting, develop policies and procedures which align to enterprise-wide business strategies and accounting professional standards, perform technical accounting diligence on prospective acquisitions, and support on the execution of the Company's strategic growth initiatives to expand on a national scale. Ms. Choe is a highly accomplished finance professional with 17 years of accounting and operational experience. Most recently, Ms. Choe served as a Partner at STK Financial where she was responsible for the financial audit and review of domestic and international clients, provided high level outsourced accounting advisory services, performed financial due diligence for mergers and acquisitions, and assisted in the preparation of 10K and 10Q financial statements and footnotes. Prior to this role, Ms. Choe served as Audit and Assurance Manager at JNK Accountancy Group, where she successfully conducted financial audits in accordance with US GAAP and IFRS measures for various domestic and international clients. She also advised clients on various topics including accounting policies, internal control, risk assessments, fraud, and new accounting standards. Ms. Choe is a certified public accountant. She received her Bachelor of Science degree in hospitality management from Florida International University and her Master of Science equivalent in accounting from the AICPA Accounting Program at Ajou University in Suwon, South Korea.
お知らせ • May 25Cardiff Lexington Corp. announced delayed 10-Q filingOn 05/24/2023, Cardiff Lexington Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 25Cardiff Lexington Corporation announced delayed amended 10-Q filingOn 08/24/2021, Cardiff Lexington Corporation announced that they will be unable to file their amended 10-Q by the deadline required by the SEC.
お知らせ • Aug 17Cardiff Lexington Corporation announced delayed 10-Q filingOn 08/16/2021, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 05Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million.Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million on June 4, 2021. Under the terms, Cardiff paid $2.5 million in cash, 0.9 million J Preferred Stock and a performance based contingent supplement payment of 0.8 million shares. Leonite Capital and an affiliated institutional investor provided a capital investment into Cardiff Lexington Series N Preferred Stock of $3.5 million which facilitated Cardiff Lexington's cash payment portion of the acquisition to the Sellers. No operational changes are planned, and current ownership will remain in place under a ten (10) year Management Agreement. The subsidiary will serve as an acquisition platform to integrate complementary healthcare service providers in neighboring markets and ancillary service providers (chiropractic, physical therapy, imaging, etc.) as we meet rapidly expanding opportunities. Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million.
